The Canada DNA Diagnostics Market was valued at $629.2 Million in 2024 and projected to reach to $905.5 Million by 2029, representing a compound annual growth rate of 7.6%. Canada's DNA diagnostics market is poised for sustained growth through 2029, driven by advancing healthcare infrastructure, increased genomic literacy among Canadian physicians, and expanding insurance coverage for diagnostic testing.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's DNA diagnostics market is valued at $629.2 million in 2024, with projections reaching $905.5 million by 2029, representing a robust 7.6% CAGR.
Canadian healthcare providers are increasingly integrating precision medicine and genomic testing into clinical practice, driven by provincial health system investments and patient demand for personalized treatment options.
Canada's strong investment in genomic research facilities and diagnostic capabilities, including partnerships with leading academic institutions, positions the nation as a key player in North American DNA diagnostics innovation.
Public and private healthcare sectors in Canada are expanding coverage for DNA diagnostic tests, supported by regulatory frameworks and growing clinical evidence supporting genomic testing across oncology, cardiology, and rare disease diagnosis.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | HPV (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 9.7% from 2024 to 2029 |
| Largest Segment | BLOOD, PLASMA, AND SERUM (Specimen) |
| Market Size Base Year (Billions) | ~USD 13.34 (2024) |
| Revenue Forecast (Billions) | ~USD 21.2 (2029) |
| Segments Covered | Offering, Technology, Specimen, Application, Type, End User |
6 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| DIAGNOSTIC LABORATORIES | 315.7 | 337.7 | 363.9 | 393.1 | 426.2 | 463.7 | 505.8 | 553.1 | 8.7 |
| HOSPITALS & CLINICS | 153.6 | 161.2 | 170.3 | 180.2 | 191.3 | 203.6 | 217.1 | 231.9 | 6.4 |
| OTHER END USERS | 88.7 | 91.5 | 95.1 | 99.1 | 103.6 | 108.7 | 114.3 | 120.6 | 4.9 |
| TOTAL | 558 | 590.4 | 629.2 | 672.4 | 721.1 | 775.9 | 837.2 | 905.5 | 7.6 |
Canada's DNA diagnostics market was valued at $629.2 million in 2024 and is expected to grow to $905.5 million by 2029.
Canada's DNA diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2029.
Key drivers include rising demand for personalized medicine, increased adoption of genetic testing, growing preventive healthcare awareness, and Canada's supportive regulatory environment for diagnostic innovation.
Non-invasive prenatal testing, cancer genomics, and pharmacogenomic applications are among the fastest-growing segments in Canada's DNA diagnostics market.
Canada represents a significant portion of North America's DNA diagnostics market, with its 7.6% CAGR reflecting strong healthcare infrastructure and government support for genomic innovation.
To determine the current size of the DNA diagnostics market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.
The four steps involved in estimating the market size are
Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.
During the primary research phase, a comprehensive approach was adopted, involving interviews with a diverse array of sources from both the supply and demand sides. These interviews aimed to gather qualitative and quantitative data essential for compiling this report. Primary sources primarily comprised industry experts spanning core and related sectors, as well as favored suppliers, manufacturers, distributors, service providers, technology innovators, and entities associated with all facets of this industry's value chain. In-depth interviews were meticulously conducted with a range of primary respondents, including key industry stakeholders, subject-matter authorities, C-level executives representing pivotal market players, and industry advisors. The objective was to obtain and authenticate critical qualitative and quantitative insights and to evaluate future potentialities comprehensively.
A breakdown of the primary respondents is provided below:

Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Roche Diagnostics Ltd. |
Area Sales Manager |
|
Danaher Corporation |
General Manger |
|
Thermo Fisher Scientific Inc. |
Consultant |
All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the DNA diagnostics market was also split into various segments and subsegments at the region and country level based on:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
DNA diagnostic tests detect and analyze variations in the sequence, structure, or expression of deoxyribonucleic acid (DNA) to diagnose diseases or medical conditions. This includes identifying indications caused by specific pathogens or determining genetic carrier status.
DNA diagnostic techniques can detect numerous diseases, such as cancer, viral diseases, and myogenic disorders. They are also employed in prenatal diagnostics and clinical diagnostic confirmation.
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for the report:
Further breakdown of the DNA diagnostics market into specific countries/regions in Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries.
Detailed analysis and profiling of additional market players (up to Five), inclusive of:
Note: Some companies are privately owned, and their revenues are unavailable in the public domain. Hence, revenues for privately owned companies will not be included in their profile. In addition, company developments that are not reported in the public domain will not be included.
Full forecast, segment splits, and company analysis for all DNA Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report